枸橼酸铋雷尼替丁三联与兰索拉唑三联及四联疗法根除幽门螺杆菌的研究

目的:观察枸橼酸铋雷尼替丁(RBC)三联疗法对根除幽门螺杆菌(Helicobacter pylori,Hp)的效果,并通过与兰索拉唑三联或四联疗法对照研究以评价不同方案的疗效及其安全性.方法:93例经胃镜证实的Hp阳性伴有明显异常的慢性胃炎患者,随机分成RBC三联组(A组,RBC 350mg 阿莫西林1g 甲硝唑400mg,bid,疗程1周)、兰索拉唑三联组(B组,兰索拉唑30mg 阿莫西林1g 甲硝唑400mg,bid,疗程1周)和兰索拉唑四联组(C组,兰索拉唑30mg 阿莫西林1g 甲硝唑400mg 枸橼酸铋钾220mg,bid,疗程1周).疗程结束4周后复查Hp感染情况,观察Hp根除率、症状缓解率及不良反应等.结果:A,B和C三组Hp根除率分别为85%,84%和90%;3组疼痛缓解率分别为86%,83%和91%.组间比较均无统计学意义(P>0.05).结论:RBC为主的三联疗法的Hp根除率与以兰索拉唑为主的三联及四联疗法相当,不良反应发生相似.

Comparison of ranitidine bismuth citrate and lansoprazole-based regimens in the treatment of Helicobacter pylori infection

Objective:To study the efficacies of ranitidine bismuth citrate (RBC)-based triple therapy with lansoprazole-based triple and quadruple therapies in the treatment of Helicobacter pylori (Hp) for one week. To evaluate the safety of the all therapies. Methods:93 patients with Hp-positive gastritis diagnosed by endoscopy were randomized to receive one of the following regimens for 7 days: group A,RBC 350mg, amoxicillin 1g, metronidazole 400mg; group B, lansoprazole 30mg, amoxicillin 1g, metronidazole 400mg; group C, lansoprazole 30mg, amoxicillin 1g, metronidazole 400mg, bismuth potassium citrate 220mg (all given twice daily for 1 week). Four weeks after finishing medication,13C- urea breath test were performed. Results: The Hp eradication rates of the group A, group B and group C were 85% ,84% and 90% respectively(P>0.05) .The pain-relieving rates of 3 groups were 86% , 83 % and 91% (P>0.05). Side effects were mild in all groups. Conclusions: RBC-based regimen is ef-fective and well tolerated for the eradication of Hp. The efficacies of Hp eradicating were similar among the three groups.